http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20210118971-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0fcbc9ca53bc68f405f71764197469b5 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-38 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-44 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4745 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-437 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4745 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P5-38 |
| filingDate | 2020-02-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_488469e31faaa8fa00eaa2567ca15167 |
| publicationDate | 2021-10-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-20210118971-A |
| titleOfInvention | Therapeutic use of relacorilant, a heteroaryl-ketone fused azadecalin glucocorticoid receptor modulator |
| abstract | Hypercortisolemia, metabolic syndrome, prediabetes, diabetes, Cushing's syndrome, Cushing's disease, hyperglycemia due to hypercortisolemia, liver disease, heart disorders, hypertension, blood clotting disorders, cancer, psychological disorders, weight gain, impaired glucose control, bone Diagnose patients suspected of suffering from disorders such as disorders (eg, osteoporosis), hypogonadism, pseudoacromegaly, pituitary tumors, functional hypercortisolism, ACTH-secreting tumors, peripheral neuropathy, dyslipidemia, and other disorders and methods and compositions for treating a patient suffering from it. The methods and compositions comprise the administration of a heteroaryl-ketone fused azadecalin glucocorticoid receptor modulator (GRM). A preferred heteroaryl-ketone fused azadecalin GRM is relacorylant ((R)-(1-(4-fluorophenyl)-6-((1-methyl-1H-pyrazol-4-yl)sulfonyl) -4,4a,5,6,7,8-hexahydro-1H-pyrazolo[3,4-g]isoquinolin-4a-yl)(4-(trifluoromethyl)pyridin-2-yl)meth rice field). In some cases, the GRM (eg, relacorilant) is administered orally. In some cases, the GRM (eg, relacorilant) is administered orally without food. |
| priorityDate | 2019-02-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 552.